Literature DB >> 17259788

Intracerebroventricular acute and chronic administration of obestatin minimally affect food intake but not weight gain in the rat.

V Sibilia1, E Bresciani, N Lattuada, D Rapetti, V Locatelli, V De Luca, F Donà, C Netti, A Torsello, F Guidobono.   

Abstract

We studied the effect of the acute central administration of obestatin on food intake and body weight in short-term starved male rats, and those of 28-day continuous intracerebroventricular (icv) infusion of obestatin in free feeding rats. In 16-h starved rats, obestatin induced a trend toward a reduction of food intake that did not reach statistical significance. In fed rats, the icv infusion of obestatin significantly decreased food consumption in the first day of treatment; but the anorexigenic effect of obestatin vanished thereafter. Interestingly, the body weight of rats infused for 28 days with obestatin was superimposable to that of the respective control at all time intervals. In all, our results indicate that the anorexigenic effect of obestatin is of little account and that the peptide does not modify energy metabolism in the long-term administration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17259788     DOI: 10.1007/BF03349204

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  13 in total

1.  Neither intravenous nor intracerebroventricular administration of obestatin affects the secretion of GH, PRL, TSH and ACTH in rats.

Authors:  Daisuke Yamamoto; Nobuko Ikeshita; Rie Daito; Elizabeth Henny Herningtyas; Keizo Toda; Kentaro Takahashi; Keiji Iida; Yutaka Takahashi; Hidesuke Kaji; Kazuo Chihara; Yasuhiko Okimura
Journal:  Regul Pept       Date:  2006-10-19

2.  Obestatin alters sleep in rats.

Authors:  Eva Szentirmai; James M Krueger
Journal:  Neurosci Lett       Date:  2006-06-23       Impact factor: 3.046

3.  Lack of interaction between peripheral injection of CCK and obestatin in the regulation of gastric satiety signaling in rodents.

Authors:  G Gourcerol; M Million; D W Adelson; Y Wang; L Wang; J Rivier; D H St-Pierre; Y Taché
Journal:  Peptides       Date:  2006-08-24       Impact factor: 3.750

4.  Obestatin does not activate orphan G protein-coupled receptor GPR39.

Authors:  Erwin Lauwers; Bart Landuyt; Lutgarde Arckens; Liliane Schoofs; Walter Luyten
Journal:  Biochem Biophys Res Commun       Date:  2006-10-19       Impact factor: 3.575

5.  Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake.

Authors:  Jian V Zhang; Pei-Gen Ren; Orna Avsian-Kretchmer; Ching-Wei Luo; Rami Rauch; Cynthia Klein; Aaron J W Hsueh
Journal:  Science       Date:  2005-11-11       Impact factor: 47.728

6.  Obestatin inhibits feeding but does not modulate GH and corticosterone secretion in the rat.

Authors:  E Bresciani; D Rapetti; F Donà; I Bulgarelli; L Tamiazzo; V Locatelli; A Torsello
Journal:  J Endocrinol Invest       Date:  2006-09       Impact factor: 4.256

7.  Central obestatin administration does not modify either spontaneous or ghrelin-induced food intake in rats.

Authors:  L M Seoane; O Al-Massadi; Y Pazos; U Pagotto; F F Casanueva
Journal:  J Endocrinol Invest       Date:  2006-09       Impact factor: 4.256

8.  Altered gastrointestinal and metabolic function in the GPR39-obestatin receptor-knockout mouse.

Authors:  Dieder Moechars; Inge Depoortere; Benoit Moreaux; Betty de Smet; Ilse Goris; Luc Hoskens; Guy Daneels; Stefan Kass; Luc Ver Donck; Theo Peeters; Bernard Coulie
Journal:  Gastroenterology       Date:  2006-10       Impact factor: 22.682

9.  GPR39 signaling is stimulated by zinc ions but not by obestatin.

Authors:  Birgitte Holst; Kristoffer L Egerod; Enrico Schild; Steve P Vickers; Sharon Cheetham; Lars-Ole Gerlach; Laura Storjohann; Carsten E Stidsen; Rob Jones; Annette G Beck-Sickinger; Thue W Schwartz
Journal:  Endocrinology       Date:  2006-09-07       Impact factor: 4.736

10.  Amylin given by central and peripheral routes inhibits acid gastric secretion.

Authors:  F Guidobono; M Coluzzi; F Pagani; A Pecile; C Netti
Journal:  Peptides       Date:  1994       Impact factor: 3.750

View more
  7 in total

1.  Low prevalence of obesity in Behçet's disease is associated with high obestatin level.

Authors:  Süleyman Serdar Koca; Murat Kara; Metin Özgen; Ramazan Dayanan; Caner Feyzi Demir; Kader Aksoy; Nevin İlhan; Emir Dönder; Ahmet Işık
Journal:  Eur J Rheumatol       Date:  2017-06-01

2.  Effect of peripheral obestatin on food intake and gastric emptying in ghrelin-knockout mice.

Authors:  I Depoortere; T Thijs; D Moechars; B De Smet; L Ver Donck; T L Peeters
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

3.  Peripheral obestatin has no effect on feeding behavior and brain Fos expression in rodents.

Authors:  Peter Kobelt; Anna-Sophia Wisser; Andreas Stengel; Miriam Goebel; Norbert Bannert; Guillaume Gourcerol; Tobias Inhoff; Steffen Noetzel; Bertram Wiedenmann; Burghard F Klapp; Yvette Taché; Hubert Mönnikes
Journal:  Peptides       Date:  2008-02-07       Impact factor: 3.750

4.  Ghrelin and obestatin levels in rheumatoid arthritis.

Authors:  Suleyman Serdar Koca; Metin Ozgen; Suleyman Aydin; Sait Dag; Bahri Evren; Ahmet Isik
Journal:  Inflammation       Date:  2008-10       Impact factor: 4.092

5.  The hungry stomach: physiology, disease, and drug development opportunities.

Authors:  Gareth J Sanger; Per M Hellström; Erik Näslund
Journal:  Front Pharmacol       Date:  2011-02-18       Impact factor: 5.810

Review 6.  Preclinical evidence of ghrelin as a therapeutic target in epilepsy.

Authors:  Tongtong Ge; Wei Yang; Jie Fan; Bingjin Li
Journal:  Oncotarget       Date:  2017-06-02

Review 7.  Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes.

Authors:  Elaine Cowan; Kerry J Burch; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2016-05-27       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.